SEC Form 4 · accession 0001209191-17-002695
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Glenning
Director
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $84.92 | Jan 4, 2017 | A | 10,000 | A | — | Jan 3, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option fully vests on January 4, 2018, subject to the reporting person's continuous service with the issuer as of the vesting date.